Nimbus® Antimicrobial Technology Proven to Provide Superior Versatility to Wound Care Clinicians
GAINESVILLE, Fla. — Oct. 11, 2011 — Quick-Med Technologies, Inc., a life sciences company that is
developing innovative technologies for the healthcare and consumer markets, announced today that
company researchers have demonstrated that NIMBUS antimicrobial technology utilized in Bioguard
Barrier Dressings offers clinicians more therapeutic flexibility than the PHMB-based antimicrobial
used in Kerlix® AMD Dressings.
In vitro studies found that Bioguard wound dressing are completely compatible with Santyl®, a frequently used collagenase debriding agent, while Kerlix AMD actually deactivates Santyl'S active ingredient. The researchers also found that Bioguard can be used without complications with Dakin's Solution®, a popular wound cleanser based on hypochlorite, while dressings with PHMB such as Kerlix® AMD should not be used because hypochlorite deactivates the active antimicrobial agent polyhexamethylene biguanide.
These studies demonstrate the benefit of Bioguard over Kerlix® AMD when used with some commonly used wound treatments. As explained by Gregory Schultz, PhD, University of Florida Research Foundation Professor and past president of the Wound Healing Society, "wound care clinicians need to understand that some combinations of wound dressings and treatments can destructively interact, reducing their effectiveness, while other combinations are potentially helpful."
"Bioguard dressings with NIMBUS antimicrobial technology offer superior versatility and have been designed to allow worry-free use in the increasingly complex wound care environment," said Albina Mikhaylova, PhD, Senior Scientist at Quick-Med Technologies. She explained "NIMBUS is an important antimicrobial technology for medical devices because it doesn't leach or suffer depletion, doesn't initiate bacterial resistance, doesn't interfere with tissue healing, and prevents odor generation.
Bioguard"® bacterial barrier wound dressings are marketed under license from Quick-Med by Derma Sciences, Inc.
The study results are summarized in a new paper entitled "The Effects of Bioguard vs. Kerlix AMD Dressings when used in combination with Dakin's Solution or SANTYL Ointment." A copy of the paper can be downloaded here.
Posted October 25, 2011
In vitro studies found that Bioguard wound dressing are completely compatible with Santyl®, a frequently used collagenase debriding agent, while Kerlix AMD actually deactivates Santyl'S active ingredient. The researchers also found that Bioguard can be used without complications with Dakin's Solution®, a popular wound cleanser based on hypochlorite, while dressings with PHMB such as Kerlix® AMD should not be used because hypochlorite deactivates the active antimicrobial agent polyhexamethylene biguanide.
These studies demonstrate the benefit of Bioguard over Kerlix® AMD when used with some commonly used wound treatments. As explained by Gregory Schultz, PhD, University of Florida Research Foundation Professor and past president of the Wound Healing Society, "wound care clinicians need to understand that some combinations of wound dressings and treatments can destructively interact, reducing their effectiveness, while other combinations are potentially helpful."
"Bioguard dressings with NIMBUS antimicrobial technology offer superior versatility and have been designed to allow worry-free use in the increasingly complex wound care environment," said Albina Mikhaylova, PhD, Senior Scientist at Quick-Med Technologies. She explained "NIMBUS is an important antimicrobial technology for medical devices because it doesn't leach or suffer depletion, doesn't initiate bacterial resistance, doesn't interfere with tissue healing, and prevents odor generation.
Bioguard"® bacterial barrier wound dressings are marketed under license from Quick-Med by Derma Sciences, Inc.
The study results are summarized in a new paper entitled "The Effects of Bioguard vs. Kerlix AMD Dressings when used in combination with Dakin's Solution or SANTYL Ointment." A copy of the paper can be downloaded here.
Posted October 25, 2011
Advertisement